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Abstract
This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2020.
Other selected articles can be found online at https://www.biomedcentral.com/collections/annualupdate2020.
Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://
www.springer.com/series/8901.
Introduction
The acute respiratory distress syndrome (ARDS) is a
clinical syndrome defined by acute onset hypoxemia
(PaO2:FiO2 ratio < 300) and bilateral pulmonary opaci-
ties not fully explained by cardiac failure or volume
overload [1]. The Berlin consensus definition of ARDS,
like the American-European Consensus definition that
preceded it, has enabled clinicians and researchers alike
to prospectively identify patients with ARDS, implement
lung protective ventilation strategies, and enroll patients
in clinical trials. ARDS remains under-recognized clinic-
ally, however; therapies are limited, and mortality re-
mains high [2]. Under-recognition of ARDS may stem in
part from the considerable clinical heterogeneity ob-
served among patients who meet standard ARDS cri-
teria. The syndrome may be triggered, for example, by
pulmonary or extrapulmonary sepsis, aspiration, trauma,
blood product transfusion, or pancreatitis. Pulmonary
infiltrates can be focal or diffuse. Hypoxemia can range
from mild to severe, and duration of respiratory failure
can be brief or prolonged. Many of these clinical varia-
tions may reflect underlying biological differences be-
tween ARDS patients that are now recognized as
important drivers of treatment response and ultimate
outcomes.
Substantial heterogeneity within the general ARDS
population has likely contributed to the failure of
experimental therapies for ARDS in recent large clinical
trials, despite promising preclinical data [3]. Identifying
subphenotypes of ARDS— more homogeneous groups
within the general ARDS population—is one approach
to untangling the clinical and biological complexity that
many believe is a barrier to discovery of successful new
treatments. By identifying meaningful but currently
unrecognized subgroups encompassed by the broad con-
sensus definition of ARDS, interventions can potentially
be tested more efficiently in targeted cohorts. Selecting
subphenotypes of patients at higher risk for poor out-
comes for enrollment in clinical trials is called prognos-
tic enrichment [4]. Selecting for patients more likely to
respond to a given therapy due to the mechanism of
benefit is called predictive enrichment [4]. Both enrich-
ment strategies are recommended by the Food and Drug
Administration to increase the efficiency of clinical trials
across all fields, either by increasing the rate of the out-
come of interest (prognostic enrichment) or by amplify-
ing the effect size (predictive enrichment). These
approaches may allow researchers to detect treatment
effects in smaller cohorts, which is especially important
in heterogeneous syndromes like ARDS. Ultimately,
however, the discovery of ARDS subphenotypes may en-
rich more than clinical trial populations: within the next
decade, these innovations could help us move from a
one-size-fits-all approach to ARDS treatment to more
effective, tailored therapies based on the clinical and bio-
logic profile of each patient.
This chapter summarizes the state of the science of
subphenotyping of ARDS patients, exploring the physio-
logic, clinical, and biologic characteristics that have been
found to identify more homogeneous subgroups within
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this heterogeneous syndrome (Table 1), and the poten-
tial implications of these advances for practicing clini-
cians in the intensive care unit (ICU) and the emergency
department.
ARDS Subphenotypes and Prognostic Enrichment
Prognostic enrichment in ARDS research involves select-
ing patients with a higher likelihood of having a particu-
lar disease-related endpoint, such as fewer ventilator-
free days or higher mortality. Beyond increasing research
efficiency, identifying subphenotypes of ARDS patients
at highest risk for poor outcomes may also lead to im-
proved risk stratification at the bedside, allowing clini-
cians to select patients more likely to benefit from inter-
facility transfer for higher level of care, or early consider-
ation of aggressive therapies such as extracorporeal
membrane oxygenation (ECMO).
Physiologic Phenotyping for Prognostic Enrichment
Risk stratification of ARDS patients is not a new strat-
egy. The Berlin definition itself stratifies ARDS into
three subgroups (Table 2) according to the degree of
hypoxemia (mild, moderate, and severe), and mortality
increases as the PaO2:FiO2 ratio decreases [1]. The ad-
vantage of this approach is that the PaO2:FiO2 ratio is
available in all patients with ARDS and does not require
expert interpretation or subjective clinical assessment.
Multiple large clinical ARDS trials have used the PaO2:
FiO2 ratio for prognostic enrichment. For example, the
ACURASYS trial of early continuous neuromuscular
blockade [5], the PROSEVA trial of prone positioning
[6], and the ROSE trial reevaluating early continuous
neuromuscular blockade [7] all targeted patients with
moderate-to-severe ARDS (PaO2:FiO2 ratio < 150
mmHg). All three of these trials had mortality endpoints,
and all three had mortality rates in the control arms that
exceeded 40%.
In addition to the PaO2:FiO2 ratio, several other
physiologic variables are known to predict poor out-
comes in ARDS. Dead space fraction [8], ventilatory ra-
tio (a simple bedside index of impaired ventilation) [9],
and driving pressure (a measurement of respiratory sys-
tem compliance) are all independently associated with
poor outcomes in ARDS [10] and more routine meas-
urement of these variables could improve prognostic en-
richment in clinical trials and risk prediction in clinical
practice.
One limitation of using these physiologic measure-
ments, however, is that these variables can rapidly
change. The application of higher positive end-
expiratory pressure (PEEP), for example, could rapidly
move a patient from one subgroup of ARDS severity to
another, or a patient who aspirates at the time of intub-
ation may develop severe hypoxemia that improves
within hours. Perhaps more fundamentally, common
physiologic characteristics in most cases do not capture
important differences in biology between ARDS patients.
A patient with transfusion-associated ARDS may have
the same PaO2:FiO2 ratio or driving pressure as a patient
with ARDS from H1N1 influenza, but their underlying
pathophysiology may be very different, and they do not
have the same risk of poor outcomes. Indeed, the Berlin
definition of ARDS is far from perfect as a predictor of
mortality, with an area under the curve of only 0.577 [1].
Clinical Phenotyping for Prognostic Enrichment
Recognizing the limitations of a purely physiologic ap-
proach to subphenotyping ARDS patients, investigators
have also examined various clinical variables to enhance
prognostic enrichment (Table 1). For example, patients
with ARDS following trauma have been found to be at
lower risk of death than non-trauma patients with ARDS
(odds ratio 0.44) [11]. Luo et al. found that despite over-
all similar mortality rates, predictors of mortality differ
between direct (pulmonary trigger) and indirect (extra-
pulmonary trigger) ARDS [12]. ARDS patients with
acute kidney injury (AKI) have been shown to have sig-
nificantly higher mortality than patients without AKI in
several cohorts [13, 14]. Thus, when attempting to iden-
tify high-risk ARDS patients, non-trauma patients and
patients with significant AKI are a higher-risk subset,
but predictors of mortality differ depending on whether
the lung injury is direct or indirect.
Beyond baseline clinical characteristics, the time-
course of ARDS is another factor that can identify pa-
tients at greater risk of poor outcomes. Both time of on-
set and duration of disease appear to hold prognostic
value. Several studies have shown that ARDS onset >48
h after ICU admission is associated with higher mortality
Table 1 Examples of factors used for identifying subphenotypes
of the acute respiratory distress syndrome (ARDS)
Physiologic Clinical Biologic
PaO2:FiO2 Trauma vs. medical Genomic
Dead space fraction Direct vs. indirect Transcriptomic
Driving pressure Focal vs. diffuse Proteomic
±Acute kidney injury Metabolomic
Table 2 The Berlin Definition of ARDS categorizes patients
according to the severity of their oxygenation deficit; increasing
severity is associated with increased mortality [1]
Severity PaO2:FiO2 ratio (mmHg) Patients (%) Mortality (%)
Mild 201–300 22 27
Moderate 101–200 50 32
Severe ≤100 28 45
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[15, 16]. Not surprisingly, rapidly improving ARDS
(ARDS that resolves within 1 day) has a better prognosis
than persistent ARDS. More interesting, however, is the
finding that most (63%) patients with rapidly improving
ARDS present with moderate or severe hypoxemia [17],
highlighting the limitations of using the PaO2:FiO2 ratio
alone to identify patients for enrollment in clinical trials.
Recognizing this issue, the PROSEVA trial of prone po-
sitioning only enrolled patients if they continued to meet
inclusion criteria (PaO2:FiO2 ratio < 150 mmHg) after
12–24 h of stabilization [7].
Radiographic patterns of pulmonary infiltrates have
also been used to sort ARDS patients into more homo-
geneous subgroups and identify those at highest risk of
death, either alone or in combination with other physio-
logic and clinical variables. One small prospective study
found that ARDS patients with non-focal infiltrates had
higher mortality compared to patients with focal radio-
graphic findings [18]. The CESAR trial of ECMO for se-
vere ARDS required a Murray Lung Score (which
incorporates chest radiography) of >3 for eligibility (or a
pH < 7.20) [19, 20]. More recently, the RALE score—de-
veloped to systematically quantify the extent and density
of alveolar infiltrates on chest radiograph—has been
shown to predict 28-day mortality with an area under
the curve of 0.82 [21].
An apparent drawback to relying exclusively on clin-
ical characteristics for phenotyping, however, is the po-
tential for misclassification. In a recent trial of
mechanical ventilation personalized according to the
presence of focal vs. diffuse infiltrates in ARDS (dis-
cussed further later), 21% of the radiographic subpheno-
types assigned at the time of randomization were
misclassified [22]. Similarly, investigators have found it
difficult to classify patients as having direct or indirect
ARDS, with 37% of cases deemed unclassifiable in one
trial [23]. Pragmatic and reliable approaches to classifica-
tion are needed to overcome the challenges inherent to
clinical phenotyping.
Biologic Phenotyping for Prognostic Enrichment
It follows that there has been growing interest in identi-
fying biologic subphenotypes of ARDS patients. Biologic
markers are considered proximal to the clinical expres-
sion of ARDS, and potentially less prone to problems
with misclassification that make clinical phenotyping so
challenging. Moreover, our understanding of ARDS biol-
ogy has advanced greatly in the past decade. We now
better understand how an initial insult causes an inflam-
matory cascade that results in further injury to the al-
veolus and its microvasculature (Fig. 1) [3]. Measuring
plasma biomarkers in ARDS can help find subgroups of
patients that share important host-response features
and/or that have worse clinical outcomes. Numerous
genomic, transcriptomic, proteomic, and metabolomic
factors have been studied for this purpose, with the
greatest depth of research focused on plasma protein
biomarkers of ARDS. These include markers of systemic
inflammation (interleukin [IL]-6, IL-8, soluble tumor ne-
crosis factor [TNF] receptor-1, IL-18), epithelial injury
(angiopoietin-2, intercellular adhesion molecule-1),
endothelial injury (soluble receptor for advanced glyca-
tion end products [sRAGE], surfactant protein-D), and
disordered coagulation (plasminogen activator inhibitor-
1, protein C), all of which have been shown to hold
prognostic value [24]. Baseline levels of sRAGE, for ex-
ample, independently predicted 90-day mortality in one
meta-analysis [25]. More recently, Rogers et al. found
that elevations in baseline plasma IL-18 levels and rising
IL-18 levels were both associated with increased mortal-
ity in sepsis-induced ARDS [26].
Using an approach to identify subgroups within a het-
erogeneous population called latent class analysis (LCA),
two distinct subphenotypes of ARDS were identified
based on combined clinical and biologic data from pa-
tients enrolled in two large clinical trial cohorts [27].
The “hyperinflammatory” subphenotype was character-
ized by enhanced inflammation, fewer ventilator-free
days, and increased mortality compared to the “hypoin-
flammatory” subphenotype (Fig. 2). These two subphe-
notypes have been found in subsequent independent
analyses of multiple other ARDS trial cohorts, and the
poor prognosis associated with the hyperinflammatory
phenotype persists [28, 29]. Using a different approach,
called hierarchical clustering, to analyze a panel of
plasma biomarkers from ARDS patients, Bos et al. iden-
tified two similar subphenotypes: a “reactive” subpheno-
type characterized by greater inflammation and
increased mortality and an “uninflamed” subphenotype
associated with better outcomes [30]. Taken together,
these findings support the idea that ARDS patients can
be stratified according to markers of inflammation for
prognostic enrichment.
The focus on proteomic profiling of ARDS patients
has been paralleled by interest in genomic, transcrip-
tomic, and metabolomic subphenotypes of ARDS, but
less progress has been made in terms of prognostic en-
richment with these strategies. Meyer et al. identified an
IL-1RN coding variant that increased risk of developing
ARDS in sepsis [31], and Zhu et al. found certain micro-
RNAs to be risk biomarkers for ARDS among critically
ill adults [32], but genomic and transcriptomic subphe-
notyping of patients with established ARDS remains
largely unexplored. In a small cohort of patients with
ARDS, Rogers et al. found a subset of patients with a
distinct metabolic profile with higher levels of numerous
metabolites in undiluted pulmonary edema fluid [33].
This “high metabolite” subphenotype was associated
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with higher mortality but, in part because of the chal-
lenges associated with analyzing pulmonary edema fluid,
these findings have yet to be reproduced in a larger
cohort.
Indeed, measurement of protein biomarkers and
“-omics” data in ARDS patients is not currently available
outside of the research setting. Furthermore, the impact
of identifying biologic subphenotype on downstream
outcomes in ARDS patients has not been prospectively
evaluated. Investigators have recently identified a “parsi-
monious” model that classifies ARDS patients as “hypo-”
or “hyperinflammatory” using only three plasma bio-
markers (IL-8, bicarbonate and protein C) [34], and
rapid analysis of biomarkers for identification of ARDS
subphenotype at the point of care is now being piloted.
Development of rapid assays is a critical step in lever-
aging the identification of ARDS subphenotypes for
prognostic enrichment in future clinical trials, and ul-
timately bringing these discoveries to the bedside.
ARDS Subphenotypes and Predictive Enrichment
In parallel with these different strategies for identifying
subgroups and phenotypes for prognostic enrichment in
ARDS, investigators have also studied how treatment ef-
fects vary by subphenotype. By finding a subphenotype-
specific treatment response retrospectively or targeting
treatment based on mechanism and biologic features, re-
searchers can then go on to prospectively test new
Fig. 1 Pathobiology of the exudative phase of ARDS. The healthy alveolar-capillary unit (left) and the exudative phase of ARDS (right). AECI type I
alveolar epithelial cell, AECII type II alveolar epithelial cell, Ang-2 angiopoietin-2, APC activated protein C, CC-16 club cell (formerly Clara cell)
secretory protein 16, CCL chemokine (CC motif) ligand, DAMP damage-associated molecular pattern, ENaC epithelial sodium channel, GAG
glycosaminoglycan, HMGB1 high-mobility group box 1 protein, KL-6 Krebs von den Lungen 6, LPS lipopolysaccharide, LTB4 leukotriene B4, MMP
matrix metalloproteinase, MPO myeloperoxidase, mtDNA mitochondrial DNA, Na+/K+ ATPase sodium-potassium ATPase pump, NF-κB nuclear
factor kappa light-chain enhancer of activated B cells, NET neutrophil extracellular trap, PAMP pathogen-associated molecular pattern, PRR pattern
recognition receptor, ROS reactive oxygen species, sICAM soluble intercellular adhesion molecule, SP surfactant protein, sRAGE soluble receptor for
advanced glycation end products, TNF tumor necrosis factor, VEGF vascular endothelial growth factor, vWF von Willebrand factor. (Reused from [3]
with permission)
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interventions in patients who are more likely to respond.
This approach provides predictive enrichment: by ampli-
fying treatment response, the power to detect a benefit
from experimental therapies increases, and discovery be-
comes more efficient. Just as biologic phenotyping of
other diseases, such as breast cancer or asthma, has led
to important improvements in patient outcomes, the
eventual goal is to deploy targeted therapies for ARDS
according to patient characteristics, moving the field
from protocolized care to precision medicine.
Physiologic Phenotyping for Predictive Enrichment
While many view physiologic parameters such as PaO2:
FiO2 ratio as purely prognostic indicators, they may pro-
vide predictive enrichment as well. As Prescott et al.
note in their discussion of ARDS clinical trial strategies,
a lower PaO2:FiO2 ratio not only identifies patients at
higher risk of death, but also reflects patients with
greater lung weight who may be more likely to benefit
from recruitment maneuvers, higher PEEP or prone po-
sitioning [35]. Similarly, one could hypothesize that
among patients with severe ARDS, those who have a
plateau pressure >30 cmH2O or an unfavorable driving
pressure despite adherence to a lung-protective ventila-
tion strategy may be more likely to benefit from “lung
rest” with ultra-low tidal volumes on ECMO.
Clinical Phenotyping for Predictive Enrichment
As discussed above, difficulty classifying patients is a
pragmatic challenge inherent to clinical phenotyping of
ARDS patients, and a major drawback to the use of clin-
ical phenotyping in both research and practice. Nonethe-
less, different clinical subphenotypes of ARDS may
reflect different underlying biology, and in some cases
have been shown to respond differently to treatment.
For example, patients with direct ARDS have higher
levels of biomarkers of epithelial injury than patients
with indirect ARDS [36], and there is low-level evidence
that patients with direct ARDS may respond differently
to recruitment maneuvers and glucocorticoids than in-
direct lung injury patients [22, 37–39]. A recent, highly
innovative randomized controlled trial compared a per-
sonalized mechanical ventilation strategy selected ac-
cording to radiographic subphenotype (focal vs. non-
focal) to standard low tidal volume ventilation in 400 pa-
tients with moderate-to-severe ARDS (LIVE trial) [22].
The intention-to-treat analysis found no difference in
outcomes between groups, but in a post hoc analysis
that excluded misclassified patients (21% of total pa-
tients), there was a mortality benefit to the personalized
mechanical ventilation intervention. These results high-
light both the promise and the peril of using subpheno-
type (in this case radiographic subphenotype) to guide
therapy: on the one hand, if patients are appropriately
classified, there may be a benefit of personalized care
over protocolized care; on the other hand, the significant
misclassification that occurs even in the relatively con-
trolled setting of a clinical trial can completely offset the
potential benefit. Regardless of this complexity, the LIVE
trial was a first step in the direction of what many view
as the future of ARDS research: leveraging subphenotype
to personalize therapy and directly comparing outcomes
to standard protocolized care.
Biologic Phenotyping for Predictive Enrichment
No trials have yet used biologic phenotyping pre-
randomization, because bedside testing of biomarkers is
not widely available. There is, however, mounting evi-
dence that biologic phenotype predicts treatment re-
sponse. In retrospective analyses, the hypo- and
hyperinflammatory phenotypes discussed above have
been observed to have differential treatment responses
to several different interventions, including PEEP and
fluid management strategies (Table 3) [27, 29]. Subphe-
notypic differences in response to simvastatin were also
observed in reanalysis of one clinical trial (HARP-2 trial)
[40], but not in a similar reanalysis of a separate trial of
rosuvastatin for ARDS (SAILS trial) [41]. While it is pos-
sible this discrepancy reflects differences in trial design
(and the particular statin that was tested), it also high-
lights the uncertainty that remains when differential
treatment response has been observed only
retrospectively.
The use of metabolomics, transcriptomics, and gen-
omics for ARDS phenotyping and predictive enrichment
is in even earlier stages than proteomic phenotyping.
Bos et al. used the “uninflamed” and “reactive” subphe-
notypes they had previously identified based on plasma
protein biomarkers to test whether there were differ-
ences in blood leukocyte gene expression between
Fig. 2 The hypoinflammatory and hyperinflammatory
subphenotypes of ARDS are associated with different biomarkers
and outcomes. These two distinct subphenotypes have been
identified by Calfee et al. in multiple previous ARDS clinical trial
cohorts [27, 29, 40, 41]. IL interleukin, bicarb bicarbonate, TNFr1
tumor necrosis factor receptor 1
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groups, and found that approximately one-third of genes
were differentially expressed. Specifically, there was up-
regulation of oxidative phosphorylation genes in the “re-
active” subphenotype, leading the authors to suggest that
for patients in this group, interventions focused on this
pathway should be explored [42]. While these data cer-
tainly merits further investigation, translating biologic
associations into effective treatments based on mechan-
ism is by no means straightforward. For example, a
retrospective analysis of a previous negative clinical trial
of recombinant IL-1 receptor antagonist for sepsis found
a treatment benefit in the subset of patients with higher
levels of baseline IL-1 receptor antagonist, arguably a
completely counterintuitive result [43].
The benefit of biologically tailored precision therapies
for ARDS remains theoretical. The translation of the in-
sights gained from studying subphenotypes of ARDS
into targeted therapies based on mechanism—and com-
parison of this precision approach to standard protoco-
lized management—is the next frontier in ARDS
research.
Beyond ARDS: Subphenotypes in Other Heterogeneous
Syndromes
As mentioned earlier, the search for subphenotypes in
ARDS is motivated in part by improvements in the
treatment of other heterogeneous diseases gained by
using a similar approach. Oncologic therapies in par-
ticular are increasingly guided by molecular pheno-
type, and this strategy has improved survival
substantially even in patients with advanced disease.
Survival with metastatic melanoma, for example, has
improved significantly since the advent of checkpoint
inhibitors and therapies targeting the BRAF V600 mu-
tation [44]. Asthma therapy has also been changed by
the identification of clinically significant subpheno-
types: patients with severe, uncontrolled eosinophilic
asthma have been found to have fewer exacerbations
with monoclonal antibodies aimed at reducing eosino-
phil activation [45].
Subphenotypes have also been identified in sepsis, an-
other heterogeneous syndrome in the critically ill that
has historically been treated with a protocolized ap-
proach. Wong et al. have developed a biomarker-based
mortality risk model for pediatric sepsis, as well as gene-
expression-based subphenotypes of pediatric septic
shock. In a retrospective analysis of a cohort of pediatric
patients with septic shock, they found that among inter-
mediate- and high-risk patients, corticosteroids were as-
sociated with a more than tenfold reduction in the risk
of a complicated course in one subphenotype but not
the other [46]. Similar subphenotyping of adult sepsis is
an area of active study. Gårdlund et al. used latent class
analysis to identify six distinct subphenotypes of septic
shock using clinical data from a previous large clinical
trial cohort [47]. Seymour et al. used a different ap-
proach (machine learning applied to electronic health
record data) and identified four subphenotypes with dif-
ferent genetic and inflammatory markers and markedly
different mortality rates [48].
Finally, there is a small but growing body of evidence
that there are meaningful subphenotypes within the het-
erogeneous post-cardiac arrest syndrome, beyond type
of arrest and initial post-resuscitation neurologic status.
For example, Bro-Jeppesen et al. have reported that IL-6,
a marker of systemic inflammation, is correlated with
poor prognosis in comatose patients resuscitated from
out-of-hospital cardiac arrest [49]. Anderson et al. found
that patients with post-resuscitation shock who had a
preserved left ventricular ejection fraction (LVEF) had
less favorable neurologic outcomes, increased organ fail-
ure, and higher mortality compared to patients with de-
pressed LVEF [50]. In addition, patients in the preserved
LVEF group exhibited a subtype-specific response to
early fluid resuscitation, with lower mortality and im-
proved neurologic outcomes associated with larger vol-
ume fluid resuscitation that was not observed in the
group with depressed LVEF. These findings suggest that
there are identifiable subphenotypes in post-cardiac ar-
rest syndrome, and that subphenotypes may be import-
ant drivers of variable treatment response.
Table 3 Subphenotype-specific treatment response in the reanalyses of outcomes in four different clinical ARDS trials
Intervention/trial cohort analyzed Hypoinflammatory subphenotype response Hyperinflammatory subphenotype response
Outcome Intervention Control Intervention Control
High vs. low PEEP/ ALVEOLI* [27] 90-day
mortality
24% high PEEP 16% low PEEP 42% high PEEP 51% low PEEP
Conservative vs. liberal fluid strategy/
FACCT* [29]
90-day
mortality
18% conservative fluid
strategy
26% liberal fluid
strategy
50% conservative fluid
strategy
40% liberal fluid
strategy
Simvastatin/ HARP-2 [40] 28-day
survival
No difference Improved survival with simvastatin (p =
0.008)
Rosuvastatin/SAILS [41] 90-day
mortality
No difference No difference
PEEP positive end-expiratory pressure; ∗p value <0.05 for interaction between treatment and subphenotype
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Conclusion
The armamentarium of therapies for patients with ARDS
remains limited and mortality remains high. While nega-
tive results in several large randomized controlled trials
of new treatments for ARDS have frustrated many, they
have also motivated multiple novel approaches to under-
standing the clinical and biologic heterogeneity among
ARDS patients. The identification of meaningful ARDS
subphenotypes—and the ways in which their outcomes
and treatment responses differ—promises prognostic
and predictive enrichment for future trials. Prospective
evaluation of methods for reliable phenotyping at the
point of care is a crucial next step in translating these
discoveries into new personalized therapies for ARDS.
Ultimately, identification of ARDS subphenotypes may
help fulfill the aspiration of precision critical care for
ARDS: replacing blunt interventions aimed at all patients
who meet diagnostic criteria with therapies tailored to
the clinical and biologic profile of each patient.
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